Business
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results
MINNEAPOLIS, March 11, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: CMS four-fold payment increase to $1,639 for Aquadex Ultrafiltration Therapy in the outpatient setting effective January 1, 2025.New data published in JACC: Heart Failure showed Aquadex ultrafiltratio
About this update from Nuwellis, Inc.
[{"type":"image","alt":"Nuwellis, Inc.","displaySize":"","headline":null,"caption":"Nuwellis, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":72,"url":"https://media.zenfs.com/en/globenewswire.com/d2460037586c5d451999b7d63383d34b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/epm_zxode7LAVlWVBg62FQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d2460037586c5d451999b7d63383d34b","width":300,"height":72}},"lazy":false},{"type":"text","content":"MINNEAPOLIS, March 11, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2024.","length":280,"tagName":"p"},{"type":"text","content":"Recent Highlights:","length":18,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"CMS four-fold payment increase to $1,639 for Aquadex Ultrafiltration Therapy in the outpatient setting effective January 1, 2025.","length":129,"tagName":"p"}]},{"val":[{"type":"text","content":"New data published in JACC: Heart Failure showed Aquadex ultrafiltration reduced heart failure events by 60% compared to IV diuretics.","length":134,"tagName":"p"}]},{"val":[{"type":"text","content":"Full year operating cost reduction of $5.9 million, or 26%, compared to the prior year.","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"Revenue of $2.3 million, a 9% decrease compared to the prior year quarter.","length":74,"tagName":"p"}]},{"val":[{"type":"text","content":"Consumables utilization growth of 21% compared to the prior year quarter.","length":73,"tagName":"p"}]},{"val":[{"type":"text","content":"Critical Care customer category revenue growth of 35% compared to the prior year quarter.","length":89,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross margin of 58.4%, compared to 54.4% in the prior year quarter.","length":67,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":653,"olType":false},{"type":"text","content":"“Our steadfast commitment to making Aquadex the standard of care for the clinical management of fluid overload resulted in fourth quarter annual consumables utilization growth of 21% and a 35% increase in revenue in Critical Care, our largest r...